|Awarded On||May 18, 2016|
|Title||Targeting EWS-FLI-1 for degradation|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Yuzuru Shiio|
Ewing sarcoma is the second most common cancer of bone and soft tissues in children and young adults and is characterized by the chromosomal translocation generating a fusion oncogene between EWS and an Ets family transcription factor, most commonly FLI-1. EWS-FLI-1 fusion accounts for 85% of Ewing sarcoma cases. Ewing sarcoma is an aggressive cancer with relatively poor long-term outcome. Overall survival is approximately 50% and the five-year survival of recurrent cases is less than 10%. Considering that current cytotoxic chemotherapies used for Ewing sarcoma are not improving the survival of metastatic or recurrent disease, a new approach for targeted therapy needs to be developed. The g...